The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor samples from 67 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback